Opinion statement
Chronic myelomonocytic leukemia (CMML) has dysplastic and proliferative features. The median age of patients with CMML is 70 years; the median survival is approximately 2 years. Various chemotherapy regimens have been used with only modest success. When the proliferative phase prevails, hydroxyurea is the treatment of choice. For younger patients with high-risk CMML, an allogeneic bone marrow transplantation should be considered. If a donor cannot be identified, then combination acute myeloid leukemia-type therapy followed by an autologous stem cell or marrow transplant should be offered. Clinical trials should be considered if available because the overall results of therapeutic interventions are far from optimal.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Bennett JM: WHO classification of the acute leukemias and myelodysplastic syndromes. Int J Hematol 2000, 72:131–133.
Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189–199.
Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic leukemia, atypical chronic myeloid and chronic myelomonocytic leukemia: proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994, 87:746–754.
Storniolo AM, Moloney WC, Rosenthal DS, et al.: Chronic myelomonocytic leukemia. Leukemia 1990, 4:766–770.
Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079–2088.
Cheson BD: The myelodysplastic syndromes: current approaches to therapy. Ann Intern Med 1990, 112:932–937.
Hellstrom-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995, 89:67–71.
Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long standing refractory anemia of patients with myelodysplastic syndromes. Blood 2001, 98:958–965.
Miller KB, Kim K, Morrison FS, et al.: The evaluation of low dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann Hematol 1992, 65:162–168.
Silverman LR, Holland JF, Weinberg RS, et al.: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993, 79:21–29.
Beran M, Shen Y, Kantarjian H, et al.: High dose chemotherapy in high risk myelodysplastic syndrome: co-variate-adjusted comparison of five regimens. Cancer 2001, 92:1999–2015.
Anderson JE, Appelbaum FR, Schoch G, et al.: Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996, 87:51–58.
Wattel E, Guerci A, Hecquet B, et al.: A randomized trial of hydroxyurea versus VP16 in advanced chronic myelomonocytic leukemia. Blood 1996, 88:2480–2487.
Beran M, Kantarjian H, O’Brien S, et al.: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996, 88:2473–2479.
Beran M, Onida F, Cortes J, et al.: Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia. Blood 2001, 98:624a.
Kroger N, Zabelina T, Guardiola P, et al.: Allogeneic stem cell transplantation for adult chronic myelomonocytic leukaemia: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2001, 98:620a.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bennett, J.M. Chronic myelomonocytic leukemia. Curr. Treat. Options in Oncol. 3, 221–223 (2002). https://doi.org/10.1007/s11864-002-0011-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-002-0011-6